Ab­b­Vie preps for an on­slaught of Hu­mi­ra biosim­i­lars in 2023, with Skyrizi and Rin­voq to fill the gap for now

Un­veiled Fri­day morn­ing, Ab­b­Vie’s Q3 re­sults and earn­ings call show a com­pa­ny brac­ing for what could be steep Hu­mi­ra loss­es with the com­ing of biosim­i­lar …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER